Will Oklo Stock Double?
Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…
Sell
18
SNTI Quote, Financials, Valuation and Earnings
Last price:
$1.98
Seasonality move
:
-16.89%
Day range:
$2.13 - $2.29
52-week range:
$1.52 - $16.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.41x
P/B ratio:
1.47x
Volume:
41.7K
Avg. volume:
276K
1-year change:
-32.04%
Market cap:
$55.6M
Revenue:
$2M
EPS (TTM):
-$23.53
Analysts' Opinion
-
Consensus RatingSenti Biosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.50, Senti Biosciences has an estimated upside of 533.8% from its current price of $2.13.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $2.13.
Fair Value
-
According to the consensus of 1 analyst, Senti Biosciences has 533.8% upside to fair value with a price target of $13.50 per share.
SNTI vs. S&P 500
-
Over the past 5 trading days, Senti Biosciences has underperformed the S&P 500 by -2.88% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Senti Biosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Senti Biosciences revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Senti Biosciences reported revenues of --.
Earnings Growth
-
Senti Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Senti Biosciences reported earnings per share of -$14.10.
Enterprise value:
21.8M
EV / Invested capital:
--
Price / LTM sales:
4.41x
EV / EBIT:
--
EV / Revenue:
12.17x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.50x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $3.5M | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$68.3M | -$68.1M | -$60.8M | -$16.3M | -$16.4M | |
| EBITDA | -$64.4M | -$62.1M | -$55M | -$14.8M | -$14.9M | |
| Diluted EPS | -$20.80 | -$38.27 | -$23.53 | -$26.50 | -$14.10 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $80.5M | $55.7M | $45.2M | |
| Total Assets | -- | -- | $161.4M | $102.2M | $82.8M | |
| Current Liabilities | -- | -- | $12.9M | $9.6M | $10.7M | |
| Total Liabilities | -- | -- | $49.1M | $46.1M | $44.9M | |
| Total Equity | -- | -- | $112.3M | $56.1M | $37.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$41.1M | -$47.8M | -$43.8M | -$11.7M | -$14.1M | |
| Cash From Investing | -$84.1M | $39.6M | $49K | -$15K | -- | |
| Cash From Financing | $119M | $814K | $53.3M | -- | -$414K | |
| Free Cash Flow | -$81.6M | -$53.3M | -$43.8M | -$11.7M | -$14.1M | |
SNTI
Sector
Market Cap
$55.6M
$34.5M
Price % of 52-Week High
12.57%
49.05%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-32.04%
-35.15%
Beta (5-Year)
--
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.23
200-day SMA
Sell
Level
$3.33
Bollinger Bands (100)
Sell
Level
2.6 - 3.82
Chaikin Money Flow
Buy
Level
14.5K
20-day SMA
Sell
Level
$2.29
Relative Strength Index (RSI14)
Sell
Level
37.84
ADX Line
Buy
Level
13.71
Williams %R
Neutral
Level
-56.6038
50-day SMA
Sell
Level
$2.85
MACD (12, 26)
Buy
Level
0.50
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Sell
Level
-5.8K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.7584)
Sell
CA Score
(Annual)
Level (-1.7921)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (4.2308)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
Stock Forecast FAQ
In the current month, SNTI has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SNTI average analyst price target in the past 3 months is $13.50.
-
Where Will Senti Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Senti Biosciences share price will rise to $13.50 per share over the next 12 months.
-
What Do Analysts Say About Senti Biosciences?
Analysts are divided on their view about Senti Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Senti Biosciences is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Senti Biosciences's Price Target?
The price target for Senti Biosciences over the next 1-year time period is forecast to be $13.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SNTI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Senti Biosciences is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of SNTI?
You can purchase shares of Senti Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Senti Biosciences shares.
-
What Is The Senti Biosciences Share Price Today?
Senti Biosciences was last trading at $1.98 per share. This represents the most recent stock quote for Senti Biosciences. Yesterday, Senti Biosciences closed at $2.13 per share.
-
How To Buy Senti Biosciences Stock Online?
In order to purchase Senti Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why a $5 Stock Is Suddenly a Cash Machine
If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…
Is Roku Stock Undervalued Now?
At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…
Stock Ideas
Buy
69
Is NVDA Stock a Buy?
Market Cap: $4T
P/E Ratio: 56x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 43x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
58
INKT alert for Jul 14
MiNK Therapeutics [INKT] is down 36.03% over the past day.
Buy
51
NEGG alert for Jul 14
Newegg Commerce [NEGG] is down 26.42% over the past day.
Buy
68
ATRO alert for Jul 14
Astronics [ATRO] is down 1.02% over the past day.
